Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Medições geradas nanomecânicas ARTIDIS para lesões mamárias precoces (ANGEL)

18 de setembro de 2026 atualizado por: ARTIDIS AG

Medições geradas nanomecânicas ARTIDIS para lesões mamárias precoces (ANGEL)

This prospective, blinded, single-arm study aims to test the performance of nanomechanical phenotype in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response compared to the gold standard of histopathological assessment. The study involves patients with suspicious breast lesions who will undergo a breast biopsy procedure indicated by standard of care. The nanomechanical phenotype will be measured on the freshly obtained breast biopsies or tissue from breast surgeries.

Visão geral do estudo

Status

Recrutamento

Condições

Descrição detalhada

Objective: To test the performance of nanomechanical phenotype tests in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response, compared to the gold standard of histopathological assessment on testing suspicious lesions.

Study Design:

This is a multi-center, blinded, single-arm study designed to collect nanomechanical signature measurement data of biopsy material taken for clinical diagnostic purposes in subjects referred for breast biopsy. Routine demographic, diagnostic and treatment data will be collected, as well as response evaluations. Subjects with a benign biopsy will be followed for a maximum of 30 days, while subjects diagnosed with breast cancer will be kept in active, routine, clinical follow-up with information collected twice yearly for the first two years and annually for years three to ten. Intermediate treatment biopsies or tissue samples from surgery may be collected at participating sites where they are performed routinely as standard of care (SOC).

All patients referred to participating study sites for a core needle or vacuum-assisted breast biopsy may be eligible for this study. All patients will be asked for written, informed consent for de-identified tissue and data collection on disease, histology characteristics, outcome, on disease related patent information, and patient reported outcomes.

The 2nd tissue core or representative core biopsies taken from the study subjects will be further investigated with the ARTIDIS platform and subsequently re-entered into the routine pathological analysis within the same day. Only two biopsies will be assessed per ART-1 device per day. One in the morning and one in the afternoon to ensure that the diagnostic biopsy can be reentered into the routine pathological analysis. The ARTIDIS measured biopsies will be marked to identify the orientation of the biopsy in the ART-1 device before re-entering the routine pathological analysis.

For malignant and benign lesions, follow up data will be extracted from the electronic medical record, as well as standard email/phone contacts performed by the study coordinator.

In order to assess the diagnostic performance of the proposed new method, it will be compared to the current gold standard. The participants cannot be randomized by study subjects with cancer vs. non cancer study subjects and will attempt to accrue a cohort representing a range of diagnostic outcomes in order to obtain a reasonable assessment of diagnostic performance.

Participants:

Patients with suspicious lesions who are referred for biopsy following routine mammography, ultrasound, MRI, and/or clinical evaluation.

Eligible subjects will be identified from each site's pool of patients by study investigators and the research team. Subjects will be asked to participate, interviewed and follow-up by explaining the possible benefit for future patients. Patients' advocates will participate in promotion of the study, as well as development of new strategies for recruitment if necessary.

Follow-up will be done by phone and/or email after consent according to study timelines, underlining future benefits of participation for other patients.

Outcome Measures:

The outcome measures will be the performance of nanomechanical phenotype tests in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response, compared to the gold standard of histopathological assessment.

Data Analysis:

Data will be analyzed using appropriate statistical methods to compare the performance of the nanomechanical phenotype test with the gold standard histopathological assessment. The full analysis set will consist of all patients, for whom both classifications of the core biopsy material are available, the one obtained from the ARTIDIS ART-1 device and the one from classical histopathological assessment.

Conclusion:

This study aims to determine the effectiveness of the nanomechanical phenotype test in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response.

Tipo de estudo

Intervencional

Inscrição (Estimado)

2706

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Barcelona
      • Barcelona, Barcelona, Espanha, 08035
        • Recrutamento
        • Hospital Universitario Vall d'Hebron
        • Contato:
        • Investigador principal:
          • Vicente Peg, MD.PhD
    • Texas
      • Dallas, Texas, Estados Unidos, 75390-9020
        • Recrutamento
        • University of Texas Southwestern Medical Center
        • Investigador principal:
          • Basak Dogan, MD
        • Contato:
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • Baylor College of Medicine
        • Investigador principal:
          • Alastair Thompson, MD
        • Contato:
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • MD Anderson Cancer Clinic - Mays Clinic
        • Contato:
        • Investigador principal:
          • Therese Bevers
    • Washington
      • Seattle, Washington, Estados Unidos, 98195
        • Recrutamento
        • University of Washington
        • Contato:
          • Erin Fannon, Research Manager
          • Número de telefone: 206.685.9770
          • E-mail: ecarney@uw.edu
        • Contato:
          • Principal Investigator Meghan Flanagan, MD
    • Basel
      • Basel, Basel, Suíça, CH-4058
        • Ativo, não recrutando
        • Claraspital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Patients aged ≥ 18 years
  • Ability to understand and the willingness to sign a written informed consent.
  • Indication for breast biopsy for diagnostic purposes
  • ECOG performance status of 0 to 3.

Exclusion Criteria:

  • Conditions that, in the investigator's opinion, might indicate that the subject is not suitable for the study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Diagnóstico
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Outro: Human subjects requiring breast biopsy

All patients referred to participating study sites for a core needle or vacuum-assisted breast biopsy are eligible for this study. Upon consent, a diagnostic biopsy will be measured by the sponsor's device before returning to the standard of care pathway.

The ARTIDIS ART-1 device is an in-vitro diagnostic device based on Atomic Force Microscope (AFM) technology. The ART-1 device uses a probe to measure the nanomechanical phenotype of tissue components. ARTIDIS nanomechanical phenotype measurements are performed on fresh tissue after it is collected via biopsy or resection.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
ARTIDIS as a sensitive diagnostic tool
Prazo: Read-out on day 30

Variable, indicating a correct classification of patients' core biopsy material as malignant with the Nanomechanical Phenotype measurement in comparison to histopathological assessment as gold-standard.

Read-out on day 30
ARTIDIS as a specific diagnostic tool
Prazo: Read-out on day 30

Variable, indicating a correct classification of patients' biopsy material as benign with the ARTIDIS Nanomechanical Phenotype measurement in comparison to histopathological assessment as gold-standard.

Read-out on day 30

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
ARTIDIS as an aid subtyping breast cancer
Prazo: Read-out on day 30

Diagnostic value (sensitivity) of subtype classification of invasive breast cancer with ARTIDIS Nanomechanical Phenotype Measurement compared to classical histopathology.

Read-out on day 30
ARTIDIS imminent progression test as an indicator of local & regional progression
Prazo: Read-out at 6 Months and annually up to 10 years

Determine the ARTIDIS test's ability to detect local and regional progression at the time of diagnosis

Read-out at 6 Months and annually up to 10 years
ARTIDIS imminent progression test as an indicator of distant progression
Prazo: Read-out at 6 Months and annually up to 10 years

Determine the ARTIDIS test's ability to detect distant progression at the time of diagnosis

Read-out at 6 Months and annually up to 10 years
ARTIDIS imminent aggressiveness rating as a predictor of the pathological treatment response for patients receiving Neoadjuvant Treatment (NAT).
Prazo: Read out at surgery

Determine how well the ARTIDIS imminent aggressiveness rating predicts complete pathological treatment response at surgery for patients receiving Neoadjuvant Treatment.

Read out at surgery
ARTIDIS imminent aggressiveness rating as a predictor of the radiological treatment response for patients receiving Neoadjuvant Treatment (NAT).
Prazo: Read out at surgery

Determine how well the ARTIDIS imminent aggressiveness rating predicts radiological treatment response at the end of Neoadjuvant Treatment for patients receiving Neoadjuvant Treatment.

Read out at surgery
ARTIDIS ARTIDIS aggressiveness rating as a predictor of local recurrence-free survival time.
Prazo: Read-out annually up to 10 years

Determine the ability of the ARTIDIS aggressiveness rating to discriminate between patients with a high risk of recurrence and those with a low risk, adjusted for the applied cancer treatment.

Read-out annually up to 10 years
ARTIDIS ARTIDIS aggressiveness rating as a predictor of disease-free survival time.
Prazo: Read-out annually up to 10 years

Determine the ability of the ARTIDIS aggressiveness rating to discriminate between patients with a high risk of suffering from further disease and those with a low risk, adjusted for the applied cancer treatment.

Read-out annually up to 10 years
ARTIDIS ARTIDIS aggressiveness rating as a predictor of overall survival.
Prazo: Read-out annually up to 10 years

Determine the ability of the ARTIDIS aggressiveness rating to discriminate between patients with a high risk of dying from any cause and those with a low risk, adjusted for the applied cancer treatment.

Read-out annually up to 10 years
ARTIDIS potential in distinguishing benign from malignant lesions with nanomechanical profiles in relation to different tissue sources.
Prazo: Read-out on day 30

Variable, indicating a correct classification of patients' biopsy material by ARTIDIS Nanomechanical Phenotype Measurement in comparison to Histopathology in relation to different tissue sources (e.g. CNB, VAB, MRI guided biopsy etc.).

Read-out on day 30

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Exploratory Objective 1: ARTIDIS as an aid for diagnostic efficacy for radiologically assessed breast lesions.
Prazo: Read-out on day 30

Diagnostic value (sensitivity) of BI-RADS 4 assessment in combination with Nanomechanical Phenotype Measurement or without Nanomechanical Phenotype Measurement with histopathological assessment as gold-standard.

Read-out on day 30
Exploratory Objective 2: ARTIDIS as an aid for radiologist to improve the reliability of BI-RADS classification.
Prazo: Read-out on day 30

Diagnostic value (sensitivity) of all BI-RADS assessments in combination with Nanomechanical Phenotype Measurement or without Nanomechanical Phenotype Measurement with histopathological assessment as gold-standard.

Read-out on day 30
Exploratory Objective 3: ARTIDIS potential in improving time to treatment initiation for patients with a malignant breast lesion in comparison to standard workflow.
Prazo: Read-out during the follow-up visits on month 6, month 12, and then annually up to 10 years

Measurement of reduction of time to treatment initiation for patients with a high aggressive malignant lesion without ARTIDIS imminent aggressiveness measurement compared to time to treatment initiation with ARTIDIS imminent aggressiveness measurement via health care navigator interviews.

Read-out during the follow-up visits on month 6, month 12, and then annually up to 10 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Alastair Thompson, MD, Baylor College of Medicine

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

2 de novembro de 2023

Conclusão Primária (Estimado)

1 de dezembro de 2026

Conclusão do estudo (Estimado)

1 de novembro de 2035

Datas de inscrição no estudo

Enviado pela primeira vez

28 de abril de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de outubro de 2023

Primeira postagem (Real)

17 de outubro de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

22 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

18 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • ART-BrC-0102

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever